Probio-M8 brings additional benefits to patients with coronary heart disease through targeted modulation of the gut-heart/brain axis

Coronary artery disease (CAD), also known as coronary heart disease, refers to myocardial dysfunction and/or organic lesions caused by coronary stenosis and insufficient blood supply, and is a common cardiovascular disease . Despite current advances in medicine and treatment strategies for CAD, CVD-related morbidity and mortality remain high . Statins are widely used to treat diseases such as dyslipidemia and atherosclerosis, but they can cause serious side effects . Studies have shown that gut flora and its derived metabolites (such as short-chain fatty acids, trimethylamine oxide, bile acids, etc. ) are related to the pathogenesis of CAD. Therefore, probiotic therapy targeting gut flora and its metabolites may It has become a novel therapeutic strategy to prevent and improve the quality of life of patients with CAD . Several studies have demonstrated that both statins and probiotics are effective in improving CAD-related symptoms, but there are fewer studies on the combined effect of the two . Therefore, this study conducted a randomized, double-blind, placebo-controlled trial to explore the synergistic effect of probiotics adjuvant conventional drugs on CAD treatment, and to further explore the potential mechanism of improving patients' symptoms . Figure 1 Microbial diversity and species-level genomic SGBs characteristics of fecal metagenomic data from patients   　　This study conducted a 6-month randomized, double-blind, placebo-controlled clinical trial . Seventy-one coronary heart disease patients were recruited and randomly divided into a probiotic group with 37 and a placebo group with 34 . The probiotic group took 20mg atorvastatin tablets and metoprolol combined with Probio-M8 bacteria powder (2g per pack, 3×10 10 CFU/packet) every day, and the placebo group took 20mg atorvastatin tablets and metoprolol every day and an equal dose of placebo for 6 months . Fecal and blood samples were collected from patients at 0, 3, and 6 months, respectively, and questionnaires were filled out and clinical indicators were recorded at 0 and 6 months . Results showed that conventional medical therapy significantly improved patients' Seattle Angina Scale (SAQ) scores, however, probiotic-adjuvant-treated patients showed greater improvement in SAQ scores at 180 days compared with placebo ( P <0. 0001) . In addition, probiotic treatment was more beneficial in alleviating symptoms of anxiety and depression ( P <0. 0001, compared with placebo at 180 days), serum interleukin-6 (IL-6) and low-density lipoprotein cholesterol (LDL-C) levels were significantly lower ( P < 0. 005, P < 0. 001, respectively) . In-depth metagenome analysis found that at 180 days, the abundance of Bifidobacterium adolescentis , Bifidobacterium animalis , Bifidobacterium bifidum and Butyricicoccus porcorum in the gut of the probiotic group was significantly increased compared with the placebo group,The abundances of Flavonifractor plautii and Parabacteroides johnsonii were significantly reduced ( P < 0. 05; Figure 1) . Furthermore, probiotic intervention significantly increased patients' gut bioactive metabolites (such as methylxanthine and malonic acid) during/after the intervention . Compared with baseline, adjuvant probiotic treatment significantly reduced serum TMA and TMAO levels, and after intervention, TMAO levels in the probiotic group were significantly lower than those in the placebo group ( P < 0. 05) . At the same time, the serum levels of L-leucine, L-valine, L-cysteine ​​and L-arginine in the probiotic group were significantly decreased, and the levels of L-serine and L-glycine were significantly increased ( P < 0. 05) . Increased serum concentrations of these amino acids may be associated with prevention of cardiovascular disease . In conclusion, probiotics Probio-M8 combined with conventional therapy can improve the therapeutic effect of CAD. The underlying mechanism may be that probiotics can improve the microbial metabolic potential and serum metabolic profile by regulating the host intestinal flora and metabolites. The significance of the gut-heart/brain axis in the management of CAD is highlighted (Fig. 2) . Figure 2 A model of probiotic-driven pathways regulating the gut-heart-brain axis   　　The study was published on March 28, 2022 in the international authoritative journal mSystems (region 2, IF=6. 496). The first author: Sun Baoqing, doctoral student Ma Teng, master student Li Yalin; corresponding author: Professor Zhang Heping .   Original link: https://journals. asm. org/doi/epub/10. 1128/msystems. 00100-22   Disclaimer: This article only represents the author's personal opinion and has nothing to do with China Probiotics Network . Its originality and the text and content stated in the text have not been verified by this site, and this site does not make any guarantee or commitment to the authenticity, completeness and timeliness of this text and all or part of its content and text. Readers are only for reference and please Verify the relevant content yourself .   Copyright Notice 1. Some articles reproduced on this site are not original, and their copyright and responsibility belong to the original author . 2. All reprinted articles, links and pictures on this website are for the purpose of conveying more information, and the source and author are clearly indicated. Media or individuals who do not wish to be reprinted can contact us for infringing information that can provide sufficient evidence. , bio149 will be deleted within 12 hours after confirmation . 3. Users are welcome to submit original articles to 86371366@qq. com, which will be published on the homepage after review, and the copyright and responsibility of the articles belong to the sender .

　　Coronary artery disease (CAD), also known as coronary heart disease, refers to myocardial dysfunction and/or organic lesions caused by coronary stenosis and insufficient blood supply, and is a common cardiovascular disease
.
Despite current advances in medicine and treatment strategies for CAD, CVD-related morbidity and mortality remain high
.
Statins are widely used to treat diseases such as dyslipidemia and atherosclerosis, but they can cause serious side effects
.
Studies have shown that gut flora and its derived metabolites (such as short-chain fatty acids, trimethylamine oxide, bile acids, etc.
) are related to the pathogenesis of CAD.
Therefore, probiotic therapy targeting gut flora and its metabolites may It has become a novel therapeutic strategy to prevent and improve the quality of life of patients with CAD
.
Several studies have demonstrated that both statins and probiotics are effective in improving CAD-related symptoms, but there are fewer studies on the combined effect of the two
.
Therefore, this study conducted a randomized, double-blind, placebo-controlled trial to explore the synergistic effect of probiotics adjuvant conventional drugs on CAD treatment, and to further explore the potential mechanism of improving patients' symptoms
.
　　This study conducted a 6-month randomized, double-blind, placebo-controlled clinical trial
.
Seventy-one coronary heart disease patients were recruited and randomly divided into a probiotic group with 37 and a placebo group with 34
.
The probiotic group took 20mg atorvastatin tablets and metoprolol combined with Probio-M8 bacteria powder (2g per pack, 3×10 ¹⁰ CFU/packet) every day, and the placebo group took 20mg atorvastatin tablets and metoprolol every day and an equal dose of placebo for 6 months
.
Fecal and blood samples were collected from patients at 0, 3, and 6 months, respectively, and questionnaires were filled out and clinical indicators were recorded at 0 and 6 months
.
Results showed that conventional medical therapy significantly improved patients' Seattle Angina Scale (SAQ) scores, however, probiotic-adjuvant-treated patients showed greater improvement in SAQ scores at 180 days compared with placebo ( P <0.
0001)
.
In addition, probiotic treatment was more beneficial in alleviating symptoms of anxiety and depression ( P <0.
0001, compared with placebo at 180 days), serum interleukin-6 (IL-6) and low-density lipoprotein cholesterol (LDL-C) levels were significantly lower ( P < 0.
005, P < 0.
001, respectively)
.
In-depth metagenome analysis found that at 180 days, the abundance of Bifidobacterium adolescentis , Bifidobacterium animalis , Bifidobacterium bifidum and Butyricicoccus porcorum in the gut of the probiotic group was significantly increased compared with the placebo group,The abundances of Flavonifractor plautii and Parabacteroides johnsonii were significantly reduced ( P < 0.
05; Figure 1)
.
Furthermore, probiotic intervention significantly increased patients' gut bioactive metabolites (such as methylxanthine and malonic acid) during/after the intervention
.
Compared with baseline, adjuvant probiotic treatment significantly reduced serum TMA and TMAO levels, and after intervention, TMAO levels in the probiotic group were significantly lower than those in the placebo group ( P < 0.
05)
.
At the same time, the serum levels of L-leucine, L-valine, L-cysteine ​​and L-arginine in the probiotic group were significantly decreased, and the levels of L-serine and L-glycine were significantly increased ( P < 0.
05)
.
Increased serum concentrations of these amino acids may be associated with prevention of cardiovascular disease
.
In conclusion, probiotics Probio-M8 combined with conventional therapy can improve the therapeutic effect of CAD.
The underlying mechanism may be that probiotics can improve the microbial metabolic potential and serum metabolic profile by regulating the host intestinal flora and metabolites.
The significance of the gut-heart/brain axis in the management of CAD is highlighted (Fig.
2)
.
 
　　The study was published on March 28, 2022 in the international authoritative journal mSystems (region 2, IF=6.
496).
The first author: Sun Baoqing, doctoral student Ma Teng, master student Li Yalin; corresponding author: Professor Zhang Heping
.

 
Original link: https://journals.
asm.
org/doi/epub/10.
1128/msystems.
00100-22

---

　　Coronary artery disease (CAD), also known as coronary heart disease, refers to myocardial dysfunction and/or organic lesions caused by coronary stenosis and insufficient blood supply, and is a common cardiovascular disease
.
Despite current advances in medicine and treatment strategies for CAD, CVD-related morbidity and mortality remain high
.
Statins are widely used to treat diseases such as dyslipidemia and atherosclerosis, but they can cause serious side effects
.
Studies have shown that gut flora and its derived metabolites (such as short-chain fatty acids, trimethylamine oxide, bile acids, etc.
) are related to the pathogenesis of CAD.
Therefore, probiotic therapy targeting gut flora and its metabolites may It has become a novel therapeutic strategy to prevent and improve the quality of life of patients with CAD
.
Several studies have demonstrated that both statins and probiotics are effective in improving CAD-related symptoms, but there are fewer studies on the combined effect of the two
.
Therefore, this study conducted a randomized, double-blind, placebo-controlled trial to explore the synergistic effect of probiotics adjuvant conventional drugs on CAD treatment, and to further explore the potential mechanism of improving patients' symptoms
.
　　This study conducted a 6-month randomized, double-blind, placebo-controlled clinical trial
.
Seventy-one coronary heart disease patients were recruited and randomly divided into a probiotic group with 37 and a placebo group with 34
.
The probiotic group took 20mg atorvastatin tablets and metoprolol combined with Probio-M8 bacteria powder (2g per pack, 3×10 ¹⁰ CFU/packet) every day, and the placebo group took 20mg atorvastatin tablets and metoprolol every day and an equal dose of placebo for 6 months
.
Fecal and blood samples were collected from patients at 0, 3, and 6 months, respectively, and questionnaires were filled out and clinical indicators were recorded at 0 and 6 months
.
Results showed that conventional medical therapy significantly improved patients' Seattle Angina Scale (SAQ) scores, however, probiotic-adjuvant-treated patients showed greater improvement in SAQ scores at 180 days compared with placebo ( P <0.
0001)
.
In addition, probiotic treatment was more beneficial in alleviating symptoms of anxiety and depression ( P <0.
0001, compared with placebo at 180 days), serum interleukin-6 (IL-6) and low-density lipoprotein cholesterol (LDL-C) levels were significantly lower ( P < 0.
005, P < 0.
001, respectively)
.
In-depth metagenome analysis found that at 180 days, the abundance of Bifidobacterium adolescentis , Bifidobacterium animalis , Bifidobacterium bifidum and Butyricicoccus porcorum in the gut of the probiotic group was significantly increased compared with the placebo group,The abundances of Flavonifractor plautii and Parabacteroides johnsonii were significantly reduced ( P < 0.
05; Figure 1)
.
Furthermore, probiotic intervention significantly increased patients' gut bioactive metabolites (such as methylxanthine and malonic acid) during/after the intervention
.
Compared with baseline, adjuvant probiotic treatment significantly reduced serum TMA and TMAO levels, and after intervention, TMAO levels in the probiotic group were significantly lower than those in the placebo group ( P < 0.
05)
.
At the same time, the serum levels of L-leucine, L-valine, L-cysteine ​​and L-arginine in the probiotic group were significantly decreased, and the levels of L-serine and L-glycine were significantly increased ( P < 0.
05)
.
Increased serum concentrations of these amino acids may be associated with prevention of cardiovascular disease
.
In conclusion, probiotics Probio-M8 combined with conventional therapy can improve the therapeutic effect of CAD.
The underlying mechanism may be that probiotics can improve the microbial metabolic potential and serum metabolic profile by regulating the host intestinal flora and metabolites.
The significance of the gut-heart/brain axis in the management of CAD is highlighted (Fig.
2)
.
 
　　The study was published on March 28, 2022 in the international authoritative journal mSystems (region 2, IF=6.
496).
The first author: Sun Baoqing, doctoral student Ma Teng, master student Li Yalin; corresponding author: Professor Zhang Heping
.

 
Original link: https://journals.
asm.
org/doi/epub/10.
1128/msystems.
00100-22

---

　　Coronary artery disease (CAD), also known as coronary heart disease, refers to myocardial dysfunction and/or organic lesions caused by coronary stenosis and insufficient blood supply, and is a common cardiovascular disease
.
Despite current advances in medicine and treatment strategies for CAD, CVD-related morbidity and mortality remain high
.
Statins are widely used to treat diseases such as dyslipidemia and atherosclerosis, but they can cause serious side effects
.
Studies have shown that gut flora and its derived metabolites (such as short-chain fatty acids, trimethylamine oxide, bile acids, etc.
) are related to the pathogenesis of CAD.
Therefore, probiotic therapy targeting gut flora and its metabolites may It has become a novel therapeutic strategy to prevent and improve the quality of life of patients with CAD
.
Several studies have demonstrated that both statins and probiotics are effective in improving CAD-related symptoms, but there are fewer studies on the combined effect of the two
.
Therefore, this study conducted a randomized, double-blind, placebo-controlled trial to explore the synergistic effect of probiotics adjuvant conventional drugs on CAD treatment, and to further explore the potential mechanism of improving patients' symptoms
.

Figure 1.
Microbial diversity and species-level genomic SGBs characterization of patient fecal metagenomic data.
　　This study conducted a 6-month randomized, double-blind, placebo-controlled clinical trial
.
Seventy-one coronary heart disease patients were recruited and randomly divided into a probiotic group with 37 and a placebo group with 34
.
The probiotic group took 20mg atorvastatin tablets and metoprolol combined with Probio-M8 bacteria powder (2g per pack, 3×10 ¹⁰ CFU/packet) every day, and the placebo group took 20mg atorvastatin tablets and metoprolol every day and an equal dose of placebo for 6 months
.
Fecal and blood samples were collected from patients at 0, 3, and 6 months, respectively, and questionnaires were filled out and clinical indicators were recorded at 0 and 6 months
.
Results showed that conventional medical therapy significantly improved patients' Seattle Angina Scale (SAQ) scores, however, probiotic-adjuvant-treated patients showed greater improvement in SAQ scores at 180 days compared with placebo ( P <0.
0001)
.
In addition, probiotic treatment was more beneficial in alleviating symptoms of anxiety and depression ( P <0.
0001, compared with placebo at 180 days), serum interleukin-6 (IL-6) and low-density lipoprotein cholesterol (LDL-C) levels were significantly lower ( P < 0.
005, P < 0.
001, respectively)
.
In-depth metagenome analysis found that at 180 days, compared with the placebo group, Bifidobacterium adolescentis , Bifidobacterium animalis , Bifidobacterium bifidum andThe abundance of Butyricicoccusporcorum was significantly increased and that of Flavonifractor plautii and Parabacteroides johnsonii was significantly decreased ( P < 0.
05; Figure 1)
.
Furthermore, probiotic intervention significantly increased patients' gut bioactive metabolites (such as methylxanthine and malonic acid) during/after the intervention
.
Compared with baseline, adjuvant probiotic treatment significantly reduced serum TMA and TMAO levels, and after intervention, TMAO levels in the probiotic group were significantly lower than those in the placebo group ( P < 0.
05)
.
At the same time, the serum levels of L-leucine, L-valine, L-cysteine ​​and L-arginine in the probiotic group were significantly decreased, and the levels of L-serine and L-glycine were significantly increased ( P < 0.
05)
.
Increased serum concentrations of these amino acids may be associated with prevention of cardiovascular disease
.
In conclusion, probiotics Probio-M8 combined with conventional therapy can improve the therapeutic effect of CAD.
The underlying mechanism may be that probiotics can improve the microbial metabolic potential and serum metabolic profile by regulating the host intestinal flora and metabolites.
The significance of the gut-heart/brain axis in the management of CAD is highlighted (Fig.
2)
.
¹⁰ P P P P Bifidobacterium adolescentis Bifidobacterium animalis Bifidobacterium bifidumButyricicoccusporcorum Flavonifractor plautii Parabacteroides johnsonii P P P

Figure 2 Model of 　　probiotic -driven regulation of gut-heart and brain axis pathways Ma Teng, Master Li Yalin; Corresponding author: Professor Zhang Heping .
Original link: https://journals.
asm.
org/doi/epub/10.
1128/msystems.
00100-22 mSystems 


 

---